Skip to content
Head to head

Ocular Therapeutix vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: OCUL · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

OCUL -53.2%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
OCULVRTX
Snapshot
Sector--Biotechnology
Last price5.57515.02
Change today-4.95%-1.08%
1-year return-52.5%+22.0%
Market cap$1.23B$130.58B
52-week range5.54 – 16.44412.27 – 568.67
Valuation
P/E (TTM)-3.8733.14
P/E percentile, own 5-yr range73rd99th
P/B2.786.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.4215.32
Net profit (TTM)$-312.43M$3.88B
Revenue (TTM)$50.38M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-11.5%+11.8%
Gross margin87.3%85.5%
Operating margin-680.9%33.1%
Net margin-648.6%30.7%
Free cash flow (TTM)$-267.04M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership95.3%96.8%
Insider activity (12mo)21 buy / 29 sell28 buy / 22 sell
Short interest (% of float)13.2%1.9%
Analyst consensus100% buy (8)95% buy / 5% hold (21)
Analyst price target$25 (+351%)$624 (+21%)
StockVane view
StockVane Quant RatingE (5)C (68)
Company
Employees2746,400
Founded20061989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.